Clinical Trials for Metastatic Castrate-Resistant Prostate Cancer-Who is Looking after the Control Patients? Questions for the Future.

Whilst there has been considerable success over the last 20 years in the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC), in this commentary we suggest that recent trends in control arms in several mCRPC trials threaten the efficient and ethical development of new therapies. We highlight that solutions must be found to accommodate commercial development with definable clinical benefit, whilst ensuring that there is robust transparency and long-term efficiencies in treatment evolution.